

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
Name	Execution Date
DELEX THERAPEUTICS INC.	04/13/2009
<b>RECEIVING PARTY DATA</b>	
Name:	YM BIOSCIENCES INC.
Street Address:	5045 Orbitor Drive
Internal Address:	Bldg. 11, Suite 400
City:	Mississauga, Ontario
State/Country:	CANADA
Postal Code:	L4W 4Y4
<b>PROPERTY NUMBERS Total: 1</b>	
Property Type	Number
Application Number:	10788466
<b>CORRESPONDENCE DATA</b>	
Fax Number:	(416)362-0823
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	416-868-1482
Email:	lsmith@ridoutmaybee.com
Correspondent Name:	Ridout & Maybee LLP
Address Line 1:	225 King Street West
Address Line 2:	10th Floor
Address Line 4:	Toronto, Ontario, CANADA M5V 3M2
ATTORNEY DOCKET NUMBER:	44893-0004
NAME OF SUBMITTER:	Charles A. Boulakia
Total Attachments: 2 source=44893-0004_confirmatory assignment#page1.tif source=44893-0004_confirmatory assignment#page2.tif	

CH \$40.00 10788466

CONFIRMATORY ASSIGNMENT

WHEREAS, **DELEX THERAPEUTICS INC.**, whose complete address is 6535 Millcreek Drive, Unit 62, Mississauga, Ontario L5N 2M2, Canada, owns an invention entitled **OPIOID DELIVERY SYSTEM** which is the subject of United States patent application No. 10/788,466;

AND WHEREAS Delex Therapeutics Inc., merged with YM Biosciences Inc., whose full office address is 5045 Orbitor Drive, Bldg. 11, suite 400, Mississauga, Ontario L4W 4Y4, Canada, and became a wholly owned subsidiary of YM Biosciences Inc., as a result of a merger agreement dated April 12, 2005;

AND WHEREAS Delex Therapeutics Inc. was dissolved on July 3, 2007, with assets transferred to the parent company, YM Biosciences Inc.;

This document confirms that, for One Dollar (\$1.00) and other good and valuable consideration, receipt of which is hereby acknowledged, **Delex Therapeutics Inc., assignor**, confirms that it has sold, assigned and transferred, and does hereby sell, assign and transfer to **YM Biosciences Inc., assignee**, and to the assignee's successors, assigns or other legal representatives, all of its right to apply for and obtain Letters Patent in the United States of America and all other countries for the invention described in U.S. patent application No. 10/788,466 entitled **OPIOID DELIVERY SYSTEM**, together with its entire right, title, property, benefit and interest for the United States and other countries in and to the invention and application and any Letters Patent of the United States or any other country which may issue for the invention;

AND **Delex Therapeutics Inc.** does hereby covenant and agree for itself, its heirs, executors and assigns to do all such things and to execute without further consideration such further assurances, applications, and other instruments as may reasonably be required to obtain Letters Patent for the said invention and for additions

44893-0004

and modifications thereto in any and all countries, and vest title thereto in **YM Biosciences Inc.**, its successors, assigns and legal representatives or nominees;

AND the Assignor and the Assignee grant to Ridout & Maybee LLP the power to insert on this assignment any further indication which may be necessary to comply with the requirements of the Patent Office for its recordal in respect of said patent application.

EXECUTED at Mississauga, Ontario, Canada, this 13<sup>th</sup> day of April, 2009.

Delex Therapeutics Inc.

per: [Signature]  
(print name) DAVID G. ARMAN  
Title: CHAIRMAN & CEO

Witness: Scott Duncan

EXECUTED at Mississauga, Ontario, Canada, this 13<sup>th</sup> day of April, 2009.

YM Biosciences Inc.

per: [Signature]  
(print name) DAVID G. ARMAN  
Title: CHAIRMAN & CEO

Witness: Scott Duncan